SCHEMBL8937357

SCHEMBL8937357

CCCOc1ccc(/C(=C\C(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2cccc(C)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CYP1A2 P05177 1/20 0.50
GPR183 P32249 1/20 0.48
HSD17B10 Q99714 2/20 0.47
TP53 P04637 2/20 0.47
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 1/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HRH2 P25021 1/20 0.44
HRH1 P35367 1/20 0.44
POLB P06746 1/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937360 1.00 ALDH1A1 (0.52) ALDH1A1L3MBTL1CYP1A2GPR183HSD17B10
SCHEMBL8937322 0.92 HPGD (0.57) ALDH1A1L3MBTL1CYP1A2GPR183HSD17B10
SCHEMBL8937319 0.92 HPGD (0.57) ALDH1A1L3MBTL1CYP1A2GPR183HSD17B10
SCHEMBL8937540 0.92 HPGD (0.57) ALDH1A1L3MBTL1CYP1A2GPR183HSD17B10
SCHEMBL8937373 0.92 ALDH1A1 (0.60) ALDH1A1L3MBTL1CYP1A2HSD17B10TP53
SCHEMBL8937368 0.92 ALDH1A1 (0.60) ALDH1A1L3MBTL1CYP1A2HSD17B10TP53
SCHEMBL8937326 0.90 ALDH1A1 (0.51) ALDH1A1L3MBTL1CYP1A2HSD17B10TP53
SCHEMBL8937330 0.90 ALDH1A1 (0.51) ALDH1A1L3MBTL1CYP1A2HSD17B10TP53
SCHEMBL8937673 0.90 ALDH1A1 (0.51) ALDH1A1L3MBTL1CYP1A2HSD17B10TP53
SCHEMBL8937626 0.88 ALDH1A1 (0.58) ALDH1A1L3MBTL1CYP1A2HSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP claimed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US claimed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP claimed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed